Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Cytotoxic Edema: Pathophysiology

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mycophenolate mofetil therapy for severe immune thrombocytopenia.

British journal of haematology·2015

Same author

A curious case of haemolysis, seizure and acute renal failure associated with pregnancy.

Journal of nephrology·2014

Same author

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2013

Same author

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.

European journal of haematology·2013

Same author

Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia.

Expert opinion on biological therapy·2013

Same author

Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist.

Expert opinion on drug discovery·2013

Search research articles

Related Experiment Video

Updated: May 20, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Immune thrombocytopenia: pathophysiologic and clinical update.

Roberto Stasi¹

¹Department of Haematology, St George's Hospital, London, UK. roberto.stasi@stgeorges.nhs.uk

Seminars in Thrombosis and Hemostasis

|July 4, 2012

Summary

Immune thrombocytopenia (ITP) is an autoimmune disease affecting platelet production and survival. Advances in treatment include rituximab and thrombopoietin-receptor agonists, offering options beyond splenectomy.

More Related Videos

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34⁺ Cells

Published on: December 27, 2017

Related Experiment Videos

Last Updated: May 20, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34⁺ Cells

Published on: December 27, 2017

Area of Science:

Immunology
Hematology

Background:

Immune thrombocytopenia (ITP) is an autoimmune disorder impacting platelet count and production.
It involves autoantibodies against platelet glycoproteins, leading to platelet destruction and suppressed megakaryopoiesis.
ITP can be primary or secondary to various conditions, including infections and other autoimmune diseases.

Purpose of the Study:

To summarize the pathophysiology of Immune thrombocytopenia (ITP).
To highlight recent therapeutic advancements in managing chronic ITP.

Main Methods:

Review of existing literature on ITP pathophysiology.
Analysis of recent clinical trial data for ITP treatments.

Main Results:

ITP involves autoantibodies, T-cell dysfunction (Th1 bias, reduced Treg activity), and potentially dysfunctional mesenchymal stem cells.
Newer treatments like rituximab and thrombopoietin-receptor agonists show significant efficacy in chronic ITP.

Conclusions:

Understanding the complex immune mechanisms in ITP is crucial for developing targeted therapies.
Effective medical treatments are now available for chronic ITP, providing alternatives to splenectomy.